Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives in Premenopausal Women With Documented Endometriosis and Associated Moderate to Severe Pain

Next Previous
Trial Profile

A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives in Premenopausal Women With Documented Endometriosis and Associated Moderate to Severe Pain

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Contraceptives (Primary) ; Elagolix (Primary)
  • Indications Dysmenorrhoea; Endometriosis; Pain
  • Focus Therapeutic Use
  • Acronyms ELARIS EM-COC
  • Sponsors AbbVie

Most Recent Events

  • 26 Nov 2024 Planned primary completion date changed from 5 Dec 2024 to 1 Mar 2029.
  • 03 May 2024 Planned End Date changed from 3 Apr 2026 to 1 Jun 2030.
  • 26 Apr 2024 Planned End Date changed from 1 Jun 2030 to 3 Apr 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top